Zobrazeno 1 - 10
of 33
pro vyhledávání: '"R. P. Arora"'
Autor:
R. C. Arora, J. K. Brown, S. Chatterjee, T. J. Gan, G. Singh, M. Z. Tong, on behalf of the POQI IX Consortium
Publikováno v:
Perioperative Medicine, Vol 13, Iss 1, Pp 1-11 (2024)
Abstract Under recognition combined with suboptimal management of right ventricular (RV) dysfunction and failure is associated with significant perioperative morbidity and mortality. The contemporary perioperative team must be prepared with an approa
Externí odkaz:
https://doaj.org/article/1dc632f52a644d3abe044579409b8743
Autor:
Amy Cheung, Kristin Cleverley, David Willis, James Fleming, Cathy Walsh, Sander L Hitzig, Roula Markoulakis, Sugy Kodeeswaran, Anthony Levitt, Simran R A Arora, Michelle Di Febo, Liisa Kuuter, Adina Hauser, Kristina Kokorelias
Publikováno v:
BMJ Open, Vol 12, Iss 11 (2022)
Introduction Mental health and/or addiction (MHA) concerns affect approximately 1.2 million children and youth in Canada, yet less than 20% receive appropriate treatment for these concerns. Youth who do not receive appropriate support may disengage f
Externí odkaz:
https://doaj.org/article/efce53b8ca71445ba810b203ac8fdc6d
Publikováno v:
Indian Journal of Urology, Vol 24, Iss 1, Pp 44-47 (2008)
Aims and Objectives: The incidence of bladder malignancy is increasing worldwide and the projected rise is 28% by 2010 for both sexes (WHO). Though intravesical adjuvant therapy with BCG is superior to any other immunotherapeutic/chemotherapeutic age
Externí odkaz:
https://doaj.org/article/439980c72c2f417495c74a9cab126ef3
Publikováno v:
Indian Journal of Urology, Vol 24, Iss 2, Pp 182-185 (2008)
Background: Overactive bladder (OAB) is a bothersome condition affecting the quality of life, financial constraint on the individual, and community. Anticholinergic drugs cannot be used for long term due to adverse side effects. Botulinum toxin has r
Externí odkaz:
https://doaj.org/article/56a1420c230140f980607bf169fcbbfa
Publikováno v:
Indian Journal of Urology, Vol 22, Iss 2, Pp 130-134 (2006)
OBJECTIVE: The aim of this study was to compare the efficacy, safety and tolerability of Dutasteride vs Finasteride in a fixed dose combination, with a uro-selective a-blocker Tamsulosin, in the management of symptomatic BPH associated with LUTS. MAT
Externí odkaz:
https://doaj.org/article/43cc15ffcec34e4683b47142d9eea5d4
Publikováno v:
Indian Journal of Urology, Vol 20, Iss 2, Pp 24-28 (2004)
Objectives: Management of pT 1 G 3 TCC of urinary bladder is always a dilemma for urologists due to its high recurrence & disease progression rate. We evaluated the role of conservative management for this subgroup with TURBT and intravesical immunot
Externí odkaz:
https://doaj.org/article/62fadc08657342169b6b8c969e3692a2
Publikováno v:
Indian Journal of Urology, Vol 20, Iss 1, Pp 54-58 (2003)
Objectives: Management of hormone resistant prostate cancer (HRCaP) is always a challenge to urologist. Mi-crotubule inhibitors have been in focus as chemothera-peutic agents in carcinoma prostate, docetaxel being the most active among such drugs. Th
Externí odkaz:
https://doaj.org/article/99faaf943f844b33a96ddd5a417907ce
Publikováno v:
Indian Journal of Urology, Vol 20, Iss 1, Pp 40-45 (2003)
Objective: The rationale of using α1, blockers in the man-agement of benign prostatic hyperplasia (BPH) is based upon blocking the adrenergic receptors which regulate urinary outflow The prostate adenoma is predominantly stromal, having 40% of smoot
Externí odkaz:
https://doaj.org/article/2e77381b3f144855b02e0f4940e4f6b0
Publikováno v:
Indian Journal of Urology, Vol 19, Iss 2, Pp 113-116 (2003)
A total 220 patients with benign prostatic hyperplasia (BPH) but not having absolute indication for surgery were enrolled for 8 weeks single label study, using doxazocin (Doxacard) 4 mg daily for their features of prostatism, with a six month follow
Externí odkaz:
https://doaj.org/article/3aad95378774467794837abf371504b3
Autor:
Reshmee Bhattacharya, Aniket Kumar Bansal, Tauheed Hasan, R. P. Arora, Laishram Rajendrakumar Singh, Gurumayum Suraj Sharma
Publikováno v:
Experimental & Molecular Medicine
Experimental and Molecular Medicine, Vol 51, Iss 2, Pp 1-13 (2019)
Experimental and Molecular Medicine, Vol 51, Iss 2, Pp 1-13 (2019)
Hyperhomocysteinemia/Homocysteinuria is characterized by an increased level of toxic homocysteine in the plasma. The plasma concentration of homocysteine is 5–15 μmol/L in healthy individuals, while in hyperhomocysteinemic patients, it can be as h